首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷核子醫學

市場調查報告書

商品編碼

1572534

放射性藥物市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Radiopharmaceuticals Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月22日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球放射性藥物市場價值為 67 億美元，預計在預測期內將以 9.8% 的年複合成長率(CAGR) 成長。這一成長主要是由慢性病患病率不斷上升、對先進診斷工具和治療的需求不斷成長以及診斷成像技術的不斷進步所推動的。正子斷層掃描 (PET) 和單光子發射電腦斷層掃描 (SPECT) 等關鍵影像技術顯著提高了診斷過程的準確性，提供了詳細的功能和分子見解，補充了傳統的解剖成像方法。

放射性藥物能夠提高診斷準確性，從而能夠及早發現並更好地管理癌症、心血管疾病和神經系統疾病等慢性疾病，進一步推動了對放射性藥物的需求。因此，人們越來越關注開發具有更高靈敏度和特異性的放射性示蹤劑，這支持了市場的擴張。

整個放射性藥物產業根據類型、放射性同位素、應用、來源、最終用途和地區進行分類。

按類型分類，市場分為治療和診斷，到2023 年，診斷將佔據市場的72.6%。成為影像技術的重要組成部分。

在放射性同位素中，Technetium-99m 因其良好的核特性以及在形成用於多種診斷應用的穩定放射性藥物方面的多功能性而佔有最大的市場佔有率。這種同位素以最小的輻射暴露提供高解析度成像的能力是其在醫學成像中廣泛應用的關鍵因素。

在應用方面，由於癌症盛行率不斷上升以及對創新診斷和治療的需求，預計癌症領域將顯著成長。放射性藥物擴大用於癌症檢測和治療，使該領域成為市場成長的關鍵驅動力。

市場也按來源細分，迴旋加速器發揮至關重要的作用，因為它們能夠生產各種可立即使用的同位素，確保放射性藥物生產的靈活性和安全性。

由於對先進診斷的需求不斷成長以及放射性藥物在改善患者治療效果方面已被證實的臨床有效性，北美在全球市場中處於領先地位。預計該地區在預測期內將出現強勁成長。

產業生態系統分析
產業影響力
- 成長動力
  - 慢性病盛行率增加
  - 對新型癌症療法的投資不斷增加
  - 診斷影像的進步
- 產業陷阱與挑戰
  - 治療和診斷程序的高成本
  - 嚴格的政府法規
成長潛力分析
報銷場景
監管環境
技術景觀
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
治療性
診斷
- 寵物
- SPECT
- 其他診斷測試

第 6 章：市場估計與預測：按放射性同位素分類，2021 - 2032 年

主要趨勢
鎝99m
鎵68
洛丁一世
氟18
銅64
鐳223
鋯89
其他放射性同位素

第 7 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
癌症
- 乳癌
- 攝護腺癌
- 肺癌
- 其他癌症類型
神經病學
心臟病學
其他應用

第 8 章：市場估計與預測：按來源分類，2021 - 2032 年

主要趨勢
迴旋加速器
核反應器

第 9 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
診斷影像中心
研究和學術機構

第 10 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

Bayer AG
Bracco
Cardinal Health Inc.
Coqui Radiopharmaceuticals Corp
Curium Pharma
Eli Lilly and Company
General Electric Company
IRE ELiT
Iso-Tex Diagnostics, Inc
Jubilant Pharmova Limited
Lantheus
Novartis AG
SHINE Technologies, LLC
Telix Pharmaceuticals Limited

簡介目錄

Product Code: 10918

The Global Radiopharmaceuticals Market was valued at USD 6.7 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 9.8% over the forecast period. This growth is primarily driven by the increasing prevalence of chronic diseases, rising demand for advanced diagnostic tools and treatments, and ongoing technological advancements in diagnostic imaging. Key imaging techniques like Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) have significantly enhanced the accuracy of diagnostic processes, offering detailed functional and molecular insights that complement traditional anatomical imaging methods.

The demand for radiopharmaceuticals is further bolstered by their ability to improve diagnostic accuracy, enabling early detection and better management of chronic conditions such as cancer, cardiovascular diseases, and neurological disorders. As a result, there is a growing focus on developing radiotracers with improved sensitivity and specificity, which supports market expansion.

The overall radiopharmaceuticals industry is segregated based on Type, Radioisotope, Application, Source, End Use, and Region.

By type, the market is segmented into therapeutics and diagnostics, with diagnostics dominating the market at 72.6% in 2023. Radioisotopes such as Technetium-99m, Iodine-131, and Fluorine-18 are essential in imaging techniques like SPECT and PET, making them pivotal for diagnostic procedures across various medical fields.

Among radioisotopes, Technetium-99m holds the largest market share due to its favorable nuclear properties and versatility in forming stable radiopharmaceuticals for multiple diagnostic applications. The ability of this isotope to provide high-resolution imaging with minimal radiation exposure is a key factor contributing to its widespread use in medical imaging.

On the application front, the cancer segment is expected to see significant growth, driven by the increasing prevalence of cancer and the need for innovative diagnostics and therapies. Radiopharmaceuticals are increasingly used in cancer detection and treatment, making this segment a key driver of market growth.

The market is also segmented by source, with cyclotrons playing a crucial role due to their ability to produce various isotopes for immediate use, ensuring flexibility and safety in radiopharmaceutical production.

North America leads the global market, driven by the growing demand for advanced diagnostics and the proven clinical effectiveness of radiopharmaceuticals in improving patient outcomes. This region is expected to see robust growth during the forecast period.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic conditions
  - 3.2.1.2 Rising investments for novel cancer therapies
  - 3.2.1.3 Advancements in diagnostic imaging
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of therapies and diagnostic procedures
  - 3.2.2.2 Stringent government regulations
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Technological landscape
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Therapeutic
5.3 Diagnostics
- 5.3.1 PET
- 5.3.2 SPECT
- 5.3.3 Other diagnostic tests

Chapter 6 Market Estimates and Forecast, By Radioisotopes, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Technetium 99m
6.3 Gallium 68
6.4 Lodine I
6.5 Fluorine 18
6.6 Copper 64
6.7 Radium 223
6.8 Zirconium 89
6.9 Other radioisotopes

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Cancer
- 7.2.1 Breast cancer
- 7.2.2 Prostate cancer
- 7.2.3 Lung cancer
- 7.2.4 Other cancer types
7.3 Neurology
7.4 Cardiology
7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Source, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Cyclotron
8.3 Nuclear reactors

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospitals
9.3 Diagnostic imaging centers
9.4 Research and academic institutes

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa